2025
POS1002 ALTERED GUT MICROBIOTA COMPOSITION IN AUTOIMMUNE DISEASE PATIENTS UNDERGOING CD19-CAR T-CELL THERAPY
Maeda Y, Wirtz S, Hagen M, Rothe T, Wirsching A, Grieshaber-Bouyer R, Gimaev I, Schmid E, Kriegel M, Müller F, Mackensen A, Schett G, Zaiss M. POS1002 ALTERED GUT MICROBIOTA COMPOSITION IN AUTOIMMUNE DISEASE PATIENTS UNDERGOING CD19-CAR T-CELL THERAPY. Annals Of The Rheumatic Diseases 2025, 84: 1114-1115. DOI: 10.1016/j.ard.2025.06.357.Peer-Reviewed Original ResearchCD19 CAR T-cell therapyCD19 CAR-T cellsT-cell therapySystemic lupus erythematosusIdiopathic inflammatory myopathiesFecal IgA levelsCD19-CART cellsSerum IgA levelsAutoimmune diseasesIgA levelsSystemic sclerosisGut microbiota compositionLupus erythematosusInfusion of CD19-CAR T cellsChimeric antigen receptor (CAR)-T cellsTransfection of T cellsSevere systemic lupus erythematosusStreptococcus speciesFecal IgA contentSecond-generation CARDrug-free remissionLong-term remissionPathogenesis of autoimmune diseasesMicrobiota compositionMixed Autoimmune Hemolytic Anemia: A Systematic Review of Epidemiology, Clinical Characteristics, Therapies, and Outcomes
Jacobs J, Raza S, Clark L, Stephens L, Allen E, Woo J, Walden R, Villalba C, Tormey C, Stanek C, Adkins B, Bloch E, Booth G. Mixed Autoimmune Hemolytic Anemia: A Systematic Review of Epidemiology, Clinical Characteristics, Therapies, and Outcomes. American Journal Of Hematology 2025 PMID: 40392014, DOI: 10.1002/ajh.27721.Peer-Reviewed Original ResearchAutoimmune hemolytic anemiaDiagnostic criteriaClinical characteristicsMixed autoimmune hemolytic anemiaMultiple lines of therapyComplex hematological disorderLines of therapyNadir hemoglobin levelsReview of epidemiologyInnovative treatment modalitiesEvaluate epidemiological patternsFrequent underlying etiologyCombination therapyHematologic malignanciesImprove patient outcomesFemale predominanceHematological disordersMulticenter studyChronic hemolysisClinical featuresTreatment modalitiesHemoglobin levelsUnderlying etiologyHemolytic anemiaAutoimmune diseasesThe role of microglia in multiple sclerosis: implications for treatment with Bruton’s tyrosine kinase inhibitors
Vermersch P, Airas L, Berger T, Deisenhammer F, Grigoriadis N, Hartung H, Magyari M, Popescu V, Pozzilli C, Pugliatti M, Van Wijmeersch B, Zakaria M, Oreja-Guevara C. The role of microglia in multiple sclerosis: implications for treatment with Bruton’s tyrosine kinase inhibitors. Frontiers In Immunology 2025, 16: 1495529. PMID: 40443664, PMCID: PMC12119304, DOI: 10.3389/fimmu.2025.1495529.Peer-Reviewed Original ResearchConceptsBruton tyrosine kinase inhibitorCentral nervous systemTyrosine kinase inhibitorsBruton's tyrosine kinaseMagnetic resonance imagingPositron emission tomographyMultiple sclerosisMicroglial functionPrimary resident immune cellsTissue repairNeural homeostasisPathogenesis of MSPathophysiology of MSResident immune cellsChronic autoimmune diseaseCentral nervous system developmentInvolvement of microgliaPotential therapeutic strategyModulating microglial functionDisease progression rateImmune surveillanceImprove patient outcomesImmune cellsAutoimmune diseasesProgressive MSChildhood adversity as a risk factor for autoimmune disease: A systematic review and meta-analysis with implications for psychiatry
Jesuthasan J, Watson C, Hafeez D, Lynch-Kelly K, Danese A, Pollak T. Childhood adversity as a risk factor for autoimmune disease: A systematic review and meta-analysis with implications for psychiatry. Brain Behavior And Immunity 2025, 128: 643-653. PMID: 40320015, DOI: 10.1016/j.bbi.2025.04.036.Peer-Reviewed Original ResearchRisk of biasChildhood adversityDisease in adulthoodMeta-analysisSystematic reviewSevere mental illnessHigh risk of biasRisk factorsExposure to childhood adversityAssociated with childhood adversityAutoimmune diseasesFunnel plot inspectionRates of childhood adversityHistory of childhood adversityPeer-reviewed studiesEnvironmental risk factorsMental illnessAutoimmune disordersEgger's testElectronic databasesAetiology of autoimmune disordersPublication biasPrevention of autoimmune diseasesEffect sizeDysregulated immune responseLuck gone cold: A trifecta of B cell mutations associates with cryoglobulinemia.
Chen K, O'Connor K. Luck gone cold: A trifecta of B cell mutations associates with cryoglobulinemia. Science Immunology 2025, 10: eadx6827. PMID: 40184441, DOI: 10.1126/sciimmunol.adx6827.Peer-Reviewed Original ResearchConceptsAutoreactive B cellsSomatic mutationsAssociated with cryoglobulinemiaB cellsMutationsAutoimmune diseasesMultimodality imaging review of retroperitoneal fibrosis
Czerniak S, Mathur M. Multimodality imaging review of retroperitoneal fibrosis. Abdominal Radiology 2025, 1-19. PMID: 40035807, DOI: 10.1007/s00261-025-04847-6.Peer-Reviewed Original ResearchRetroperitoneal fibrosisSecondary causesEvaluation of retroperitoneal fibrosisAssociated with autoimmune diseasesNonspecific clinical presentationIgG4 related diseasePotential diagnostic pitfallsDiffusion weighted imagingMagnetic resonance imagingAdvanced imaging techniquesPET/CT imagingClinical presentationMultimodality imaging reviewVenous stenosisClinical featuresDiagnostic pitfallsFibroinflammatory diseaseImaging findingsAutoimmune diseasesImaging reviewInflammatory disordersIdiopathic diseaseTreatment approachesImaging appearanceImaging modalitiesAn international perspective on the future of systemic sclerosis research
Abraham D, Black C, Denton C, Distler J, Domsic R, Feghali-Bostwick C, Gourh P, Hinchcliff M, Kolling F, Kuwana M, Lafyatis R, Landegren U, Mahoney J, Martin J, Matucci-Cerinic M, McMahan Z, Mora A, Mouthon L, Rabinovitch M, Rojas M, Rubin K, Trojanowska M, Varga J, Whitfield M, Gabrielli A, Krieg T. An international perspective on the future of systemic sclerosis research. Nature Reviews Rheumatology 2025, 21: 174-187. PMID: 39953141, DOI: 10.1038/s41584-024-01217-2.Peer-Reviewed Original ResearchConceptsSystemic sclerosisSystemic sclerosis researchHistory of systemic sclerosisInnovative clinical trial designsSystemic autoimmune diseaseEarly pathogenetic eventClinical trial designCollaborative global effortAutoimmune phenomenaImprove patient outcomesDisease activityMicrovascular dysfunctionClinical historyEmergency therapyAutoimmune diseasesDisease-modifying treatmentsTissue fibrosisSingle-cell RNA sequencingClinical heterogeneityEffective disease-modifying treatmentsPersonalized therapyAnimal modelsComplex pathogenesisEffective treatmentNext-generation sequencingTranslocating gut pathobiont Enterococcus gallinarum induces TH17 and IgG3 anti-RNA–directed autoimmunity in mouse and human
Gronke K, Nguyen M, Fuhrmann H, Santamaria de Souza N, Schumacher J, Pereira M, Löschberger U, Brinkhege A, Becker N, Yang Y, Sonnert N, Leopold S, Martin A, von Münchow-Klein L, Pessoa Rodrigues C, Cansever D, Hallet R, Richter K, Schubert D, Daniel G, Dylus D, Forkel M, Schwinge D, Schramm C, Redanz S, Lassen K, Manfredo Vieira S, Piali L, Palm N, Bieniossek C, Kriegel M. Translocating gut pathobiont Enterococcus gallinarum induces TH17 and IgG3 anti-RNA–directed autoimmunity in mouse and human. Science Translational Medicine 2025, 17: eadj6294. PMID: 39908347, DOI: 10.1126/scitranslmed.adj6294.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusAutoimmune diseasesToll-like receptor 8Gut pathobiontsHuman adaptive immune responseLong-term sequelaeAdaptive immune responsesHuman T cellsChronic autoimmune diseaseHuman monocyte activationContribution to autoimmunityAutoimmune hepatitisAutoantibody titersAnti-<i>E.Autoimmune pathophysiologyLupus modelT-helperLifelong immunosuppressionTargeted therapyT cellsDisease activityLupus erythematosusAutoantibody responseMonocyte activationImmune responseP-1503. Dual β-Lactam Approach for Treatment of Mycobacterium abscessus Infections in Adults – Results in 19 Patients
Kalyatanda G, Dousa K, Lyons H, Mardourian M, Rhodes J, Iakovidis A, El-Helou G, Wilson B, Daley C, Holland S, Kreiswirth B, Nguyen D, Shin E, Kurz S, Johnson J, Bonomo R. P-1503. Dual β-Lactam Approach for Treatment of Mycobacterium abscessus Infections in Adults – Results in 19 Patients. Open Forum Infectious Diseases 2025, 12: ofae631.1672. PMCID: PMC11778049, DOI: 10.1093/ofid/ofae631.1672.Peer-Reviewed Original ResearchSubspecies abscessusB-lactamAssociated with high cure ratesIn vitro susceptibility resultsMulti-drug regimensCurrent treatment regimensSolid organ transplantationHigh cure ratesTime to initiationOptimize treatment outcomesMab infectionSynergy testClinical cureImmunocompromised patientsPulmonary infectionDiscontinued treatmentTreatment regimensCase reportClinical outcomesCure rateImmunocompromised individualsAutoimmune diseasesTreatment successEarly treatmentCulture conversionElucidating the role of autoreactive T cells and B cells in autoimmune hepatitis
Yasumizu Y, Hafler D. Elucidating the role of autoreactive T cells and B cells in autoimmune hepatitis. Journal Of Clinical Investigation 2025, 135: e188538. PMID: 39817449, PMCID: PMC11735092, DOI: 10.1172/jci188538.Peer-Reviewed Original ResearchLupus and inflammatory bowel disease share a common set of microbiome features distinct from other autoimmune disorders
Zhou H, Balint D, Shi Q, Vartanian T, Kriegel M, Brito I. Lupus and inflammatory bowel disease share a common set of microbiome features distinct from other autoimmune disorders. Annals Of The Rheumatic Diseases 2025, 84: 93-105. PMID: 39874239, PMCID: PMC11868722, DOI: 10.1136/ard-2024-225829.Peer-Reviewed Original ResearchProtein-protein interaction analysisMicrobial signaturesMicrobial profilesEffector-like proteinsSignaling pathwayInterleukin-12 signaling pathwayDisease mechanismsBacteria-derived proteinsMetagenomic datasetsMicrobiome featuresMicrobial underpinningsFunctional genesMicrobial biomarkersInteraction analysisMicrobial influenceInflammatory bowel diseaseMicrobial mechanismsGlucocorticoid signalingProteinGlucocorticoid receptorCritical roleAutoimmune diseasesPathwayBowel diseasePotential importanceEpidemiology and patient characteristics of the US myasthenia gravis population: real-world evidence from a large insurance claims database
Miller-Wilson L, Arackal J, Edwards Y, Schwinn J, Rockstein K, Venker B, Nowak R. Epidemiology and patient characteristics of the US myasthenia gravis population: real-world evidence from a large insurance claims database. BMJ Neurology Open 2025, 7: e001076. PMID: 40556711, PMCID: PMC12186037, DOI: 10.1136/bmjno-2025-001076.Peer-Reviewed Original ResearchYears of continuous follow-upMyasthenia gravisContinuous insurance coverageContinuous follow-upFollow-upIncident patientsIncident cohortRetrospective claims analysisRare autoimmune diseaseInsurance Claims DatabaseOral steroidsAcetylcholinesterase inhibitorsTreatment paradigmSustained disease controlAutoimmune diseasesEffective therapyMG incidencePatient characteristicsEpidemiology of myasthenia gravisClaims databasePatientsExacerbationCohortMG populationPrevalence ratesContribution of cellular immune dysregulation to myasthenia gravis pathology
Bayer A, Nowak R, O’Connor K. Contribution of cellular immune dysregulation to myasthenia gravis pathology. International Review Of Neurobiology 2025 DOI: 10.1016/bs.irn.2025.04.035.Peer-Reviewed Original ResearchMyasthenia gravisPersistence of autoimmunityB cell compartmentAbnormal immune responseDevelopment of TResponse to treatmentCellular compartmentsImpaired neuromuscular transmissionImmunopathology of MGTolerance checkpointsComplex immunopathologyImmune dysregulationPrevent autoimmunityT cellsAutoantibody productionPathological responseAutoimmune disordersB cellsDisease developmentAutoimmune diseasesDisease progressionImmune responseMultifactorial diseaseImmune systemNeuromuscular transmission
2024
Antigen-specific immune therapy (CNP-106) for treatment of generalised myasthenia gravis: rationale and design of first-in-human randomised controlled trial
Brew S, Frey M, McCarthy D, Elhofy A, Nowak R. Antigen-specific immune therapy (CNP-106) for treatment of generalised myasthenia gravis: rationale and design of first-in-human randomised controlled trial. BMJ Neurology Open 2024, 6: e000836. PMID: 39720510, PMCID: PMC11667273, DOI: 10.1136/bmjno-2024-000836.Peer-Reviewed Original ResearchMyasthenia gravisAntigen-specific immune therapyAntigen-specific T cellsB-cell-mediated autoimmune diseasesImmune tolerance therapyPlacebo-controlled trialGeneralised myasthenia gravisMG subjectsSerious side effectsClinical trial authorisationFood and Drug AdministrationAntigen-specific autoimmunityInstitutional review boardTolerated therapyAChR antibodiesDouble-blindImmune therapyPrimary endpointRandomised controlled trialsSecondary endpointsPathogenic antibodiesT cellsCurrent therapiesAutoimmune diseasesClinical scoresAberrant zonal recycling of germinal center B cells impairs appropriate selection in lupus
Sanchez G, Hirsch E, VanValkenburg A, Mayer D, Gbedande K, Francis R, Song W, Antao O, Brimmer K, Lemenze A, Stephens R, Johnson W, Weinstein J. Aberrant zonal recycling of germinal center B cells impairs appropriate selection in lupus. Cell Reports 2024, 43: 114978. PMID: 39527476, PMCID: PMC11682828, DOI: 10.1016/j.celrep.2024.114978.Peer-Reviewed Original ResearchGerminal centersB cellsDifferentiation of autoreactive B cellsLoss of MYCResponse to CD40 signalingPolyclonal B cell activationB cell dysregulationAccumulation of plasma cellsAutoreactive B cellsB cell activationGC B cellsB cell cycleProduction of autoantibodiesB cell signalingDecreased mutation frequencyRepertoire diversityPlasma cellsAutoimmune diseasesPersistent infectionCD40 SignalingDisease progressionMutation frequencyReduced proliferationLupusLight zoneAutoimmune Diseases and Risk of Non‐Hodgkin Lymphoma: A Mendelian Randomisation Study
Shi X, Wallach J, Ma X, Rogne T. Autoimmune Diseases and Risk of Non‐Hodgkin Lymphoma: A Mendelian Randomisation Study. Cancer Medicine 2024, 13: e70327. PMID: 39506244, PMCID: PMC11540836, DOI: 10.1002/cam4.70327.Peer-Reviewed Original ResearchConceptsRisk of non-Hodgkin lymphomaNon-Hodgkin's lymphomaAutoimmune diseasesMendelian randomisationType 1 diabetesAssociated with risk of non-Hodgkin lymphomaWeak instrument biasNon-Hodgkin lymphoma subtypesTwo-sample MRNon-Hodgkin lymphoma riskRisk factorsSusceptibility to type 1 diabetesMendelian randomisation studiesCohorts of European ancestryAssociated with riskNo significant associationPotential pleiotropyPotential risk factorsUK BiobankFinnGen studyNon-HodgkinHaematological malignanciesRandomised studyEuropean ancestrySignificant associationEpitope-anchored contrastive transfer learning for paired CD8+ T cell receptor–antigen recognition
Zhang Y, Wang Z, Jiang Y, Littler D, Gerstein M, Purcell A, Rossjohn J, Ou H, Song J. Epitope-anchored contrastive transfer learning for paired CD8+ T cell receptor–antigen recognition. Nature Machine Intelligence 2024, 6: 1344-1358. DOI: 10.1038/s42256-024-00913-8.Peer-Reviewed Original ResearchPeptide-major histocompatibility complexT cellsEpitope-specific T cellsImmune responseResidue-level interactionsPredicted binding strengthSpike-specific immune responsesTCR-based immunotherapyTumor-associated antigensT cell antigen recognitionPredicted binding specificityAdaptive immune responsesTCR cross-reactivityTCR repertoireCross-reactivityBinding specificityAutoimmune diseasesImmunodominant epitopesContact residuesAntigen recognitionHistocompatibility complexTCRImmunotherapyDistance matrixT-cell receptor-antigen recognitionTricky Ts play possum to propagate autoimmune disease.
Panicker A, O'Connor K. Tricky Ts play possum to propagate autoimmune disease. Science Immunology 2024, 9: eadt4136. PMID: 39365872, DOI: 10.1126/sciimmunol.adt4136.Peer-Reviewed Original ResearchConceptsAutoimmune diseasesAntigen-specific T cellsPropagating autoimmune diseasesB cell supportT cellsMacrophage membrane-camouflaged biomimetic nanoparticles for rheumatoid arthritis treatment via modulating macrophage polarization
Zhou R, Xue S, Cheng Y, Chen Y, Wang Y, Xing J, Liu H, Xu Y, Lin Y, Pei Z, Wei X, Ding J, Li S, Wang K, Yao F, Zhao Y, Ding C, Hu W. Macrophage membrane-camouflaged biomimetic nanoparticles for rheumatoid arthritis treatment via modulating macrophage polarization. Journal Of Nanobiotechnology 2024, 22: 578. PMID: 39300463, PMCID: PMC11414146, DOI: 10.1186/s12951-024-02822-9.Peer-Reviewed Original ResearchConceptsCollagen-induced arthritisNanotherapeutic systemInflamed jointsRheumatoid arthritisMacrophage polarizationModulating macrophage polarizationDelay disease progressionDebilitating autoimmune diseaseChronic joint inflammationComprehensive in vitroAnti-inflammatory M2 phenotypeReduced synovial inflammationEnhanced cellular uptakeIntra-articular injectionRheumatoid arthritis treatmentPro-inflammatory M1Treatment optionsAutoimmune diseasesRepolarize macrophagesBiomimetic nanoparticlesDisease progressionMouse modelNanoparticlesTherapeutic strategiesSide effectsThe Teplizumab Saga: The Challenge of Not Getting Lost in Clinical Translation.
Chatenoud L, Herold K, Bach J, Bluestone J. The Teplizumab Saga: The Challenge of Not Getting Lost in Clinical Translation. Cold Spring Harbor Perspectives In Medicine 2024, a041600. PMID: 39284671, DOI: 10.1101/cshperspect.a041600.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply